AgeX Therapeutics Reports Second Quarter 2022 Financial Results
AgeX Therapeutics, Inc. (AGE)
Company Research
Source: Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.Liquidity and Capital ResourcesDuring the first quarter of 2022, AgeX borrowed the final $0.5 million of its available credit under its 2020 Secured Convertible Facility Agreement with Juvenescence Limited (“Juvenescence”), and entered into a new Secured Convertible Promissory Note (the “Secured Note”) pursuant to which Juvenescence has agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000 of the line of credit and used $7,160,000 to refinance the principal and the loan origination fees under its 2019 Loan Agreement with Juvenescence.During the three months ended June 30, 2022, AgeX borrowed an additional $2.0 million under the Secured Note, and as of August 12, 2022, AgeX ha
Show less
Read more
Impact Snapshot
Event Time:
AGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGE alerts
High impacting AgeX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AGE
News
- Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics [Yahoo! Finance]Yahoo! Finance
- AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsGlobeNewswire
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXXPR Newswire
- AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGEBusiness Wire
AGE
Sec Filings
- 3/26/24 - Form SC
- 3/22/24 - Form 10-K
- 3/22/24 - Form 8-K
- AGE's page on the SEC website